Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~26 mi. (Lausanne, Switzerland, +199 more cities)

CHUV (centre hospitalier universitaire vaudois) ( Site 0712)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~26 mi. (Lausanne, Switzerland, +144 more cities)

Centre Hospitalier Universitaire Vaudois

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

~26 mi. (Lausanne, Switzerland, +34 more cities)

CHUV (centre hospitalier universitaire vaudois) ( Site 0333)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

~26 mi. (Lausanne, Switzerland, +21 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)

Melanoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

~26 mi. (Lausanne, Switzerland, +27 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)

Melanoma

lenvatinib, +3 more drugs

immunotherapy, +1 more type

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

~26 mi. (Lausanne, Switzerland, +30 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)

Melanoma

lenvatinib, +4 more drugs

immunotherapy, +2 more types

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

~26 mi. (Lausanne, Switzerland, +24 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)

Melanoma

MK-4830, +3 more drugs

immunotherapy

A Study of SGN-B6A in Advanced Solid Tumors

~26 mi. (Lausanne, Switzerland, +10 more cities)

University Hospital Lausanne CHUV

HER2 Negative

Bladder Carcinoma, +9 more conditions

SGN-B6A

targeted therapy

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

~26 mi. (Lausanne, Switzerland)

CHUV Oncology Department

ER Negative, +2 more biomarkers

Breast Carcinoma

CMP-001, +1 more drug

immunotherapy, +2 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~68 mi. (Genève, Switzerland, +93 more cities)

Hopitaux Universitaires de Geneve HUG ( Site 1602)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~68 mi. (Genève, Switzerland, +145 more cities)

Hopitaux Universitaires de Geneve HUG ( Site 1706)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~68 mi. (Genève, Switzerland, +105 more cities)

Hopitaux Universitaires de Geneve HUG. ( Site 1406)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy